Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
Academy Sites Books Clinical CME E-mail Journals Links Medline Parents Pharmaceuticals Professional Research Teaching Web Portals Internet Course
Brief Description: The study will include 120 participants aged 8 and up with Duchenne, Becker, or autosomal recessive limb-girdle (specifically: LGMD 2C-2F and 2I) muscular dystrophies that have no clinical cardiac symptoms. Participants will be randomized to one of four arms: CoQ10 alone, Lisinopril alone, CoQ10 and Lisinopril or No study medication. Randomization will be stratified by ambulatory status and corticosteroid use. The study will last 24 months with visits at Months 1, 2, 3, 6, 9, 12, 18 and 24.
The study is also posted onClinicalTrials.gov.
Contact Information: For more information, please contact Lauren Hache, MS, CGC; phone: 412-383-7207; email: email@example.com
IRB Status: The study is currently IRB approved at the following centers: Children's Hospital of Pittsburgh of UPMC in Pittsburgh, PA; Children's National Medical Center in Washington, DC; Carolinas Medical Center in Charlotte, NC; Children's Memorial Hospital in Chicago, IL; and Washington University in St. Louis, MO. Other US and International centers will be added. For more information please contact Lauren Hache.
Sponsorship: This multi-center research study is sponsored by the Department of Defense.
Go back to Seeking Patients page
Last revised 08-Feb-2011 by Steven Leber